28 results
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
. In connection with this engagement, Landos requested that Jefferies evaluate the fairness, from a financial point of view, to holders of shares (other … transaction. The Board of Directors also discussed the potential engagement of an investment bank to assist the Board of Directors in evaluating
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
advisor in connection with a possible sale, disposition or other business transaction involving Landos. In connection with this engagement, Landos … received from AbbVie with respect to a potential licensing transaction. The Board of Directors also discussed the potential engagement
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
in writing, arising out of or relating to the employment or engagement of any Company Associate. Since January 1, 2021, the Company has complied in all … based upon arrangements made by or on behalf of the Company. The Company has made available to Parent or its Representatives, the engagement letter
8-K
EX-2.1
LABP
Landos Biopharma Inc
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
of or relating to the employment or engagement of any Company Associate. Since January 1, 2021, the Company has complied in all material respects with all … by or on behalf of the Company. The Company has made available to Parent or its Representatives, the engagement letter pursuant to which Jefferies LLC
8-K
EX-99.1
qlmgd r3f
4 Jan 24
Regulation FD Disclosure
8:05am
8-K
EX-99.2
5m2b64
12 May 23
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
8:40am
PRE 14A
tn2flz vrzcc
10 Apr 23
Preliminary proxy
4:20pm
8-K
EX-99.2
22qmuixr
11 Aug 22
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
8:54am
DEF 14A
xicexhk2h37rgr9c
28 Apr 22
Definitive proxy
4:16pm
8-K
EX-99.1
1n14z41
8 Oct 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
pak2s78538x qmyf7e
22 Sep 21
Regulation FD Disclosure
8:00am
10-K
tvi jpv6ww6mope3fg4
31 Mar 21
Annual report
5:03pm
424B4
p1yoxbto14zj04f9
4 Feb 21
Prospectus supplement with pricing info
5:02pm